A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/08/2011	WO2011012912A3 New granulating process and thus prepared granulate
12/08/2011	WO2011008923A3 Olopatadine nasal spray regimen for children
12/08/2011	WO2010128401A9 Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
12/08/2011	WO2010120389A8 Polymeric drug delivery systems and processes for producing such systems
12/08/2011	WO2010114425A8 Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum
12/08/2011	WO2010102148A3 An improved dry powder drug delivery system
12/08/2011	WO2009065193A8 Treatment of aspirin resistance with betaine and/or betaine enriched molasses
12/08/2011	US20110301697 Manufacture, method and use of drug-eluting medical devices for permanently keeping blood vessels open
12/08/2011	US20110301617 System and Method for Immobilizing a Tick on a Host
12/08/2011	US20110301568 Systems and Methods to Treat Cardiac Pacing Conditions
12/08/2011	US20110301525 Biomaterials for tissue replacement
12/08/2011	US20110301452 Microcapsule for local treatment of a tumor and method for positioning a magnetic gradient field guiding magnetic nanoparticles to a target location as well as apparatus for positioning a magnetic gradient field
12/08/2011	US20110301339 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110301338 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110301337 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110301248 Compositions and methods of delivery of pharmacological agents
12/08/2011	US20110301245 (r)-2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril formulaitons, andthe use of such formulations in the treatment of conditions mediated by the serotonin transporter
12/08/2011	US20110301244 Fast acting naratriptan composition
12/08/2011	US20110301243 Novel method
12/08/2011	US20110301242 Inhibitors of Cathepsin S for Prevention or Treatment of Obesity-Associated Disorders
12/08/2011	US20110301241 New halo active aromatic sulfonamide organic compounds and uses therefor
12/08/2011	US20110301240 Conditioning composition
12/08/2011	US20110301239 Use of novel lipid mediators to inhibit angiogenesis
12/08/2011	US20110301238 Seizure related disorders and therapeutic methods thereof
12/08/2011	US20110301236 HeLa-C3 Apoptosis Inducer from Garcinia paucinervis
12/08/2011	US20110301235 Organoselenium compounds and uses thereof
12/08/2011	US20110301234 Formulations of ladostigil tartrate
12/08/2011	US20110301233 Novel Polyisoprenylated Benzophenone Derivatives from Garcinia paucinervis
12/08/2011	US20110301232 Process of extracting procyanidins by alkaline hydrolysis
12/08/2011	US20110301231 Lipase inhibiting composition
12/08/2011	US20110301229 Methods and compositions for the specific inhibition of gene expression by double-stranded rna
12/08/2011	US20110301227 Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms
12/08/2011	US20110301225 Compounds and Methods for Reducing the Recruitment and/or Migration of Polymorphonuclear Cells
12/08/2011	US20110301224 Methods and compositions for the specific inhibition of gene expression by double-stranded rna
12/08/2011	US20110301222 Combination therapy for the treatment of cancer
12/08/2011	US20110301221 Diagnosis, prognosis and treatment of glioblastoma multiforme
12/08/2011	US20110301220 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
12/08/2011	US20110301219 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
12/08/2011	US20110301218 MODIFIED snRNAs FOR USE IN THERAPY
12/08/2011	US20110301217 Selective Glycosidase Inhibitors and Uses Thereof
12/08/2011	US20110301216 Anticancer and antimicrobial compounds from antarctic extremophilic microorgansims
12/08/2011	US20110301215 Inhibitors of plasma kallikrein
12/08/2011	US20110301214 Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
12/08/2011	US20110301213 Use of pilocarpine for hypoptyalism treatment
12/08/2011	US20110301212 Method for treating proliferative disorders associated with protooncogene products
12/08/2011	US20110301211 Antagonists of lysophosphatidic acid receptors
12/08/2011	US20110301210 Use of pramipexole to treat amyotrophic lateral sclerosis
12/08/2011	US20110301209 Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
12/08/2011	US20110301208 Viral and fungal inhibitors
12/08/2011	US20110301207 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia
12/08/2011	US20110301205 Isoxazole derivatives for use as fungicides
12/08/2011	US20110301204 Administration regime for nitrocatechols
12/08/2011	US20110301203 Chemical compounds
12/08/2011	US20110301202 Spla2 inhibitor conjugate compounds and methods of use
12/08/2011	US20110301201 Dabigatran for percutaneous interventional cardiac catheterisation
12/08/2011	US20110301200 Thyroid receptor ligands
12/08/2011	US20110301199 Compositions and methods for treating myelodysplastic syndrome
12/08/2011	US20110301198 Compositions and methods for treating myelodysplastic syndrome
12/08/2011	US20110301196 Trypsin-like serine protease inhibitors, and their preparation and use
12/08/2011	US20110301195 Triazolothiadiazole inhibitor of c-met protein kinase
12/08/2011	US20110301194 Method for Determining Treatment Efficacy
12/08/2011	US20110301193 Methods and compositions of targeted drug development
12/08/2011	US20110301192 Inhibitors of Cyclin Kinase Inhibitor p21
12/08/2011	US20110301191 Methods of treatment using selective 5-ht2a inverse agonists
12/08/2011	US20110301190 Polymorphic forms of a gabaa agonist
12/08/2011	US20110301189 Stable pharmaceutical compositions of rapamycin esters
12/08/2011	US20110301188 Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents
12/08/2011	US20110301187 Bis [o-(14-benzoylaconine-8-yl)] esters
12/08/2011	US20110301186 Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease
12/08/2011	US20110301185 Cancer treatment method
12/08/2011	US20110301184 Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor
12/08/2011	US20110301183 Chemical synthesis of a highly potent epothilone
12/08/2011	US20110301182 Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
12/08/2011	US20110301181 halogen-substituted compounds
12/08/2011	US20110301180 Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration
12/08/2011	US20110301179 Naphthamides as anticancer agents
12/08/2011	US20110301177 Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
12/08/2011	US20110301176 Imidazothiazole derivatives having proline ring structure
12/08/2011	US20110301175 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
12/08/2011	US20110301174 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
12/08/2011	US20110301173 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
12/08/2011	US20110301172 Combination of dpp-iv inhibitor, ppar antidiabetic and metmorformin
12/08/2011	US20110301171 Inhibitors of JNK
12/08/2011	US20110301170 Inhibitors of JNK
12/08/2011	US20110301169 Therapies for Treating Cancer Using Combinations of COX-2 Inhibitors and Antimetabolites
12/08/2011	US20110301168 Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
12/08/2011	US20110301167 PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
12/08/2011	US20110301166 Method for the prevention of thromboembolic disorders
12/08/2011	US20110301165 Method for treating and preventing arthritis
12/08/2011	US20110301164 Method of administering ophthalmic fluids
12/08/2011	US20110301163 Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
12/08/2011	US20110301162 Aurora kinase modulators and methods of use
12/08/2011	US20110301161 Benzimidazole inhibitors of leukotriene production
12/08/2011	US20110301160 Inhibitors of P38 and Methods of Using the Same
12/08/2011	US20110301159 Kinase inhibitor compounds
12/08/2011	US20110301158 Aryl carbonyl derivatives as therapeutic agents
12/08/2011	US20110301157 Bicyclic amides as kinase inhibitors
12/08/2011	US20110301156 Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions
12/08/2011	US20110301155 Indazole compounds for activating glucokinase
12/08/2011	US20110301154 Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anticancer activity

1 ... 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 ... 7860